The effect of histidine ammonia-lyase on some murine tumours.
The histidine ammonia-lyase from bacterial strain CAMR 5315 was partially purified to assess its effect on the growth of murine tumours. This strain was selected as the source after an extensive screening programme for histidine ammonia-lyases. The enzyme was partially purified by ammonium sulphate fractionation, chromatography on DEAE-cellulose and Sephadex G-150. The enzyme reduced circulating L-histidine levels in Wistar rats and in mice persisted with a half-life of 6-7 h. Neither LDH virus nor chemical modification with ethylacetimidate increased the half-life as observed with L-asparaginase and L-glutaminase. The enzyme was tested in mice against Ehrlich carcinoma, L5178Y lymphoblastic leukaemia, Mc/S sarcoma, B16 melanoma, P8157 mastocytoma, P1798 lymphosarcoma and the Gardner 6C3HED lymphosarcoma. The only tumours to show sensitivity to the enzyme were the Mc/S sarcoma against which a 65% increase in life span was observed at the highest enzyme dose, 1000 U/kg on alternate days over 14 days and the Ehrlich ascites carcinoma where cures were obtained at 250 U/kg on alternate days over 14 days, but only at inocula levels of 10(5) and 10(3) cells/animal respectively.
D000642:Ammonia-Lyases / Q000627:therapeutic use*; D000818:Animals; D001419:Bacteria / Q000201:enzymology; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D004353:Drug Evaluation, Preclinical; D006638:Histidine Ammonia-Lyase / Q000302:isolation & purification / Q000378:metabolism / Q000627:therapeutic use*; D007700:Kinetics; D007942:Leukemia, Experimental / Q000188:drug therapy*; D051379:Mice; D012513:Sarcoma, Experimental / Q000188:drug therapy*; D013045:Species Specificity
D000642:Ammonia-Lyases; D006638:Histidine Ammonia-Lyase